NASDAQ:FLXN

Flexion Therapeutics - FLXN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: $9.12
▼
$9.12
50-Day Range: $9.12
▼
$9.44
52-Week Range: $4.30
▼
$13.66

Volume: N/A
Average Volume: 1.18 million shs
Market Capitalization: $458.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Flexion Therapeutics (NASDAQ:FLXN) Stock

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FLXN Stock News Headlines

September 21, 2022 | seekingalpha.com

PCRX Pacira BioSciences, Inc.

September 1, 2022 | thestreet.com

Coherus BioSciences Inc. News

July 2, 2022 | thestreet.com

Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka

January 13, 2022 | thestreet.com

Why Flexion Therapeutics (FLXN) Stock Is Plummeting in After-Hours Trading Today

November 3, 2021 | finance.yahoo.com

Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark

November 1, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations

October 30, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Flexion Therapeutics, Inc. - FLXN

October 27, 2021 | finance.yahoo.com

Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to Decline

October 21, 2021 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ESBK, FLXN, COLB, CXP; Shareholders are Encouraged to Contact the Firm

October 13, 2021 | finance.yahoo.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Flexion Therapeutics, Inc. (Nasdaq - FLXN)

October 13, 2021 | nasdaq.com

Flexion Therapeutics (NASDAQ:FLXN) shareholders are up 53% this past week, but still in the red over the last five years

October 13, 2021 | marketwatch.com

Flexion Therapeutics Shares Soar on Pacira BioSciences Deal >FLXN

October 12, 2021 | businesswire.com

FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion ...

October 12, 2021 | finance.yahoo.com

Pacira Biosciences to Snap Up Flexion Therapeutics; Shares Pop

October 12, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Flexion Therapeutics, Inc. Merger

October 11, 2021 | markets.businessinsider.com

Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher

October 11, 2021 | businesswire.com

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to ...

October 11, 2021 | finance.yahoo.com

Flexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Flexion Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FLXN

October 11, 2021 | finance.yahoo.com

Shareholder Alert: Ademi LLP investigates whether Flexion Therapeutics, Inc. has obtained a Fair Price in its transaction with Pacira

October 11, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Flexion Therapeutics, Inc. with Pacira BioSciences, Inc.

October 1, 2021 | finance.yahoo.com

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 8, 2021 | finance.yahoo.com

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 2, 2021 | finance.yahoo.com

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee

August 30, 2021 | finance.yahoo.com

Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know

August 25, 2021 | finance.yahoo.com

Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?

See More Headlines

Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FLXN Company Calendar

Last Earnings: 5/12/2021
Today: 12/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FLXN
CUSIP: N/A
CIK: 1419600
Web: www.flexiontherapeutics.com
Phone: (781) 305-7777
Fax: 781-202-3399
Employees: 257
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,710,000.00
Net Margins: -100.32%
Pretax Margin: -100.32%
Return on Equity: N/A
Return on Assets: -44.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.38
Quick Ratio: 4.05

Sales & Book Value

Annual Sales: $85.55 million
Price / Sales: 5.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.34) per share
Price / Book: -26.82

Miscellaneous

Outstanding Shares: 50,321,000
Free Float: 45,727,000
Market Cap: $458.93 million
Optionable: Optionable
Beta: 1.53

Key Executives

Michael D. Clayman
President, Chief Executive Officer & Director

Fred Driscoll
Chief Financial Officer

William T. Andrews
Chief Medical Officer

Carolyn Beaty Scimemi
Chief Compliance Officer & Head-Legal Affairs

Christina Willwerth
Chief Strategy Officer

Key Competitors

View All Competitors

FLXN Stock - Frequently Asked Questions

How were Flexion Therapeutics' earnings last quarter?: Flexion Therapeutics, Inc. (NASDAQ:FLXN) issued its quarterly earnings results on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analysts' expectations of $24.61 million.
What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?: 46 employees have rated Flexion Therapeutics Chief Executive Officer Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among the company's employees.
What other stocks do shareholders of Flexion Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

What is Flexion Therapeutics' stock symbol?: Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
What is Flexion Therapeutics' stock price today?: One share of FLXN stock can currently be purchased for approximately $9.12.
How much money does Flexion Therapeutics make?: Flexion Therapeutics (NASDAQ:FLXN) has a market capitalization of $458.93 million and generates $85.55 million in revenue each year. The specialty pharmaceutical company earns $-113,710,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.
How many employees does Flexion Therapeutics have?: The company employs 257 workers across the globe.
How can I contact Flexion Therapeutics?: Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The official website for the company is www.flexiontherapeutics.com. The specialty pharmaceutical company can be reached via phone at (781) 305-7777, via email at ir@flexiontherapeutics.com, or via fax at 781-202-3399.

This page (NASDAQ:FLXN) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Flexion Therapeutics - FLXN Stock Forecast, Price & News

About Flexion Therapeutics (NASDAQ:FLXN) Stock

FLXN Stock News Headlines

FLXN Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

FLXN Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info